KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Efficacy and Safety of Intranasal Bencycloquidium Bromide in Nasal Symptoms of Common Cold: a Phase 3, Multicenter, Randomised, Double-blind, Placebo-controlled Trial.

Lixiu He, Ling Yang, Haiying Yan, Yousheng Chen, Yuanyuan Liu, Chengling Zhao, Dang Lin, Fang Zhang, Maofeng Liu, Qiong Tang, Nali Zhang, Wenjun Li, Suhua Ao, Xunchao Liu, Wuzhuang Sun, Liang Dong, Shufeng Xu, Chuntao Liu

QJM hcaf331

PMID41476148
PMCID-
DOI10.1093/qjmed/hcaf331
发表日期2025-12-31
摘要

摘要

BACKGROUND: Common cold is one of the most prevalent illnesses affecting human health. Nasal symptoms are the most bothersome and characteristic manifestations, yet few safe and effective treatments are currently available. AIM: This phase 3, randomised, double-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of bencycloquidium bromide (BCQB) nasal spray in nasal symptoms of common cold. METHODS: Participants with cold symptoms for ≤48 hours and a rhinorrhea visual analogue scale (VAS) score ≥5 were enrolled. Participants were randomized 1:1 to receive either BCQB or placebo for 4 ± 1 days. Patients self-recorded VAS scores for rhinorrhea, sneezing, nasal congestion and itching daily. Efficacy and safety were assessed. RESULTS: Totals of 480 patients were randomized and treated. The area under the curve (AUC) for rhinorrhea VAS scores over treatment period was significantly lower in the BCQB group than in the placebo group (13.01 ± 7.19 vs. 16.01 ± 8.00; P < 0.001). Daily improvement in the average rhinorrhea VAS score was significantly greater in the BCQB group from day 2 through day 4 (P < 0.005). BCQB also demonstrated significant efficacy for nasal congestion (AUC: 10.90 ± 7.42 vs. 13.63 ± 8.64; P < 0.001) and sneezing (AUC: 7.84 ± 7.18 vs. 9.30 ± 8.64; P = 0.046). The incidence of adverse events (AEs) was similar between the two groups, and no severe AEs were reported. BCQB was well-tolerated, with no systemic anticholinergic adverse effects observed. CONCLUSIONS: BCQB nasal spray is effective and safe for treating rhinorrhea, nasal congestion, and sneezing associated with common cold. TRIAL REGISTRATION: The trial was registered at chictr.org.cn (ChiCTR2500107341).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。